Zaltrap

Zaltrap (aflibercept) is an intravenous medication used alongside other therapies to treat certain cancers. It works by blocking blood vessel growth in tumors. This overview covers its uses, effects, and safety notes for informational purposes only.

Aflibercept, sold as Zaltrap, is primarily used in combination with other cancer treatments to slow tumor progression. It is prescribed for metastatic colorectal cancer in patients whose disease has worsened after prior therapy. The medication targets vascular endothelial growth factor (VEGF), reducing blood supply to tumors. Patients often ask, 'what is aflibercept used for' in oncology settings.

Aflibercept may help slow disease progression by interfering with blood vessel formation in tumors. Common effects include fatigue, diarrhea, and decreased appetite. Some patients report mouth sores or weight loss during treatment. These effects vary by individual and should be discussed with a healthcare provider.

Aflibercept is administered intravenously under medical supervision, requiring careful monitoring for side effects. Patients with bleeding disorders or recent surgery may need special precautions. Blood pressure and protein levels in urine should be checked regularly. Always inform your doctor about current medications and health conditions before starting treatment.

Aflibercept may interact with blood thinners, NSAIDs, or other drugs affecting blood clotting. Combining it with certain chemotherapy agents could increase side effects like low blood cell counts. Live vaccines should be avoided during treatment. Alcohol use may worsen side effects such as fatigue or nausea.